Your search for supplemental oxygen returned 6 results

The update was based on data from the COV-BARRIER study.

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.

Updated on 6/16 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.*    AB201 (ARCA biopharma): a selective inhibitor of tissue factor being developed as a potential treatment for COVID associated coagulopathy. Clinical testing is expected to begin in the second half of 2020. Acalabrutinib (AstraZeneca): a…

Sarilumab is currently marketed under the brand name Kevzara for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to 1 or more disease-modifying antirheumatic drugs.

Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.